ClinicalTrials.gg

Program

fexofenadine

Also written as “Fexofenadine”, “Fexofenadine Tablets 180 mg” and “fexofenadine/Allegra (M016455)”.

Its studies are mostly in Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial · Rhinitis · Asthma, led by 7 companies.

Furthest: phase 4, since Mar 10, 200830 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi160 open or runningphase 4since Mar 10, 2008Sep 5, 2002none ahead
Dr. Reddy's Laboratories50 open or runningphase 1since Feb 9, 2010Feb 9, 2010none ahead
Organon30 open or runningphase 4since Oct 30, 2008Oct 30, 2008none ahead
Teva Pharmaceutical Industries20 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatris20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Bayer10 open or runningphase 4since Nov 8, 2011Nov 8, 2011none ahead
Handok10 open or runningphase 4since Dec 1, 2005Dec 1, 2005none ahead

Also a collaborator on its studies: achillion-a-wholly-owned-subsidiary-of-alexion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Sep 5, 2002.

  1. Aug 22, 2008Phase 4 study in Rhinitis, Allergic, PerennialSanofi · NCT00741897 · 264 enrolled · Philippines
  2. Oct 30, 2008Organon's first study: phase 4 study in Rhinitis, Allergic, SeasonalNew to OrganonOrganon · NCT00783133 · 131 enrolled
  3. Nov 19, 20082 phase 4 studies in Rhinitis, Allergic, SeasonalOrganon · NCT00794768, NCT00794248
  4. Jan 30, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00835640, NCT00835276
  5. Feb 9, 2010Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01066767, NCT01066754
  6. May 27, 20102 phase 1 studies in HealthyDr. Reddy's Laboratories · NCT01133483, NCT01133470
  7. Nov 15, 20102 phase 3 studiesSanofi · NCT01244230, NCT01244217
  8. Mar 1, 2011Phase 3 study in Rhinitis SeasonalSanofi · NCT01306721 · 520 enrolled · Japan
  9. Nov 8, 2011Bayer's first study: phase 4 study in RhinitisNew to BayerBayer · NCT01469234 · 255 enrolled
  10. Jun 26, 2013Phase 1 study in HealthyDr. Reddy's Laboratories · NCT01888718 · 80 enrolled · India
  11. Jun 22, 2014Phase 4 study in Rhinitis, Allergic, PerennialSanofi · NCT02175485 · 24 enrolled · Japan
  12. Jan 11, 2023Phase 3 study in Rhinitis, Allergic, SeasonalSanofi · NCT05692154 · 95 enrolled · Canada
  13. Jan 31, 2023Phase 4 study in Rhinitis, Allergic, PerennialSanofi · NCT05720455 · 203 enrolled · India
  14. Feb 22, 2024Phase 1 study in Healthy VolunteersSanofi · NCT06284902 · 25 enrolled · Canada

TargetBeta

HRH1 →read by rule
“Histamine H1 receptor antagonist”ChEMBL 37, by rule

Other programs on HRH1

ProgramCompanyFurthest phaseStudies
desloratadineruleOrganonphase 440
bilastinerulefaes-farma-s-aphase 419
DiphenhydramineruleJohnson & Johnsonphase 416

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06284902Healthy Volunteers · Canada1CompletedSanofiMay 8, 202425
NCT05720455Rhinitis, Allergic, Perennial · India4CompletedSanofiDec 5, 2025203
NCT05692154Rhinitis, Allergic, Seasonal · Canada3CompletedSanofiMar 14, 202395
NCT02175485Rhinitis, Allergic, Perennial · Japan4CompletedSanofiJun 201424
NCT01888718Healthy · India1CompletedDr. Reddy's LaboratoriesFeb 201180
NCT01469234Rhinitis4CompletedBayerNov 2011255
NCT01306721Rhinitis Seasonal · Japan3CompletedSanofiApr 2011520
NCT01244230Dermatitis, Atopic · Japan3CompletedSanofiJul 2011100
NCT01244217Rhinitis Perennial · Japan3CompletedSanofiJul 2011100
NCT01133483Healthy · India1CompletedDr. Reddy's LaboratoriesApr 200738
NCT01133470Healthy · India1CompletedDr. Reddy's LaboratoriesFeb 200754
NCT01066767Healthy · Canada1CompletedDr. Reddy's LaboratoriesMay 200230
NCT01066754Healthy · Canada1CompletedDr. Reddy's LaboratoriesMay 200244
NCT00835640Healthy · United States1CompletedTeva Pharmaceutical IndustriesJan 200224
NCT00835276Healthy · United States1CompletedTeva Pharmaceutical IndustriesMar 200260
NCT00794768Rhinitis, Allergic, Seasonal4CompletedOrganonJul 2003118
NCT00794248Rhinitis, Allergic, Seasonal4CompletedOrganonMay 2003122
NCT00783133Rhinitis, Allergic, Seasonal4CompletedOrganonJun 1, 2003131
NCT00741897Rhinitis, Allergic, Perennial · Philippines4CompletedSanofiDec 2003264
NCT00649376Healthy · United States1CompletedViatrisNov 200368
NCT00647985Healthy · United States1CompletedViatrisNov 200328
NCT00638118Rhinitis, Allergic · United States4CompletedSanofi48
NCT00637884Cat Induced Allergic Rhinitis4CompletedSanofi70
NCT00637611Rhinitis, Allergic, Seasonal · United States4CompletedSanofi1,010
NCT00637585Rhinitis, Allergic · United States4CompletedSanofi42
NCT00637455Rhinitis, Allergic, Seasonal · United States4CompletedSanofi72
NCT00636870Rhinitis, Allergic · United States4CompletedSanofi220
NCT00261079Pruritus · Korea, Republic of4CompletedHandok435
NCT00044824Asthma · United States, Costa Rica, Guatemala and more3CompletedSanofiOct 20031,000
NCT00044811Asthma · United States, Costa Rica, Guatemala and more3CompletedSanofiOct 20031,000

How it is read

Names in the registry

  • “Fexofenadine”, 14 entries
  • “fexofenadine”, 4 entries
  • “Fexofenadine Tablets 180 mg”, 2 entries
  • “fexofenadine/Allegra (M016455)”, 2 entries
  • “Fexofenadine HCl”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.